文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

英格兰COVID-19脉搏血氧远程监测项目对死亡率和医疗资源利用的人群影响:基于阶梯楔形设计的全国分析

Population-level impact of a pulse oximetry remote monitoring programme on mortality and healthcare utilisation in the people with COVID-19 in England: a national analysis using a stepped wedge design.
PubMed 文献 · Emerg Med J · 2022-04-13
一句话结论全国CO@h项目实施期与死亡率无关联,但ED就诊、急诊入院和重症监护入院几率分别增加12%、12%和24%, enrolment低可能稀释效应。

该研究采用回顾性队列的阶梯楔形实施前后设计,纳入英格兰全部106个CCG中2020年10月1日至2021年5月3日SARS-CoV-2 PCR阳性、年龄≥65岁或临床极度脆弱者,排除养老院居民。实施CO@h项目前后比较28天内全因死亡、ED就诊、急诊入院、重症监护入院和总住院时长。实施期与死亡率和住院时长无关联,但与ED就诊(OR增加12%,95%CI 6%-18%)、急诊入院(OR增加12%,95%CI 5%-20%)和入院者重症监护(OR增加24%,95%CI 5%-47%)几率增加相关。在 enrolment≥10%或20%的站点二次分析中,任何结局均无显著关联。

要点

  • 纳入217650例合格者,仅5527例(2.5%)有enrolment数据,项目总enrolment低。
  • 实施期与28天内全因死亡无关联,与总住院时长也无关联。
  • 实施期ED就诊几率增加12%(95%CI 6%-18%),急诊入院几率增加12%(95%CI 5%-20%)。
  • 入院者重症监护入院几率增加24%(95%CI 5%-47%)。
  • 在enrolment≥10%或20%的站点二次分析中,任何结局均无显著关联。

适用人群与场景

  • 英格兰全部106个CCG中实施本地CO@h项目的地区,2020年10月1日至2021年5月3日SARS-CoV-2 PCR阳性、有症状、年龄≥65岁或临床极度脆弱者;排除养老院居民。

研究设计与关键结果

  • 研究类型:回顾性队列研究,采用阶梯楔形实施前后设计;纳入英格兰全部106个CCG,合格人群217650人,仅5527人(2.5%)有enrolment数据。
  • 主要终点(阳性检测后28天内):实施期与全因死亡无关联,与总住院时长无关联。
  • 实施期与ED就诊几率增加12%相关(95%CI 6%-18%),与急诊入院几率增加12%相关(95%CI 5%-20%)。
  • 实施期与入院者重症监护入院几率增加24%相关(95%CI 5%-47%)。
  • 二次分析:在enrolment≥10%或20%的CO@h站点,任何结局指标均无显著关联。

证据类型、等级与局限

  • 证据类型:回顾性队列研究(阶梯楔形实施前后设计)。
  • 局限:enrolment低于预期,可能稀释了项目在人群水平的效果。

对床旁实践的改变

  • 作者认为,人群水平上CO@h项目实施期与死亡率无关联,观察到医疗服务利用小幅增加;低于预期的enrolment可能稀释了项目在人群水平的效果。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: To identify the population-level impact of a national pulse oximetry remote monitoring programme for COVID-19 (COVID Oximetry @home (CO@h)) in England on mortality and health service use.

METHODS: We conducted a retrospective cohort study using a stepped wedge pre-implementation and post-implementation design, including all 106 Clinical Commissioning Groups (CCGs) in England implementing a local CO@h programme. All symptomatic people with a positive COVID-19 PCR test result from 1 October 2020 to 3 May 2021, and who were aged ≥65 years or identified as clinically extremely vulnerable were included. Care home residents were excluded. A pre-intervention period before implementation of the CO@h programme in each CCG was compared with a post-intervention period after implementation. Five outcome measures within 28 days of a positive COVID-19 test: (i) death from any cause; (ii) any ED attendance; (iii) any emergency hospital admission; (iv) critical care admission and (v) total length of hospital stay.

RESULTS: 217 650 people were eligible and included in the analysis. Total enrolment onto the programme was low, with enrolment data received for only 5527 (2.5%) of the eligible population. The period of implementation of the programme was not associated with mortality or length of hospital stay. The period of implementation was associated with increased health service utilisation with a 12% increase in the odds of ED attendance (95% CI: 6% to 18%) and emergency hospital admission (95% CI: 5% to 20%) and a 24% increase in the odds of critical care admission in those admitted (95% CI: 5% to 47%). In a secondary analysis of CO@h sites with at least 10% or 20% of eligible people enrolled, there was no significant association with any outcome measure.

CONCLUSION: At a population level, there was no association with mortality before and after the implementation period of the CO@h programme, and small increases in health service utilisation were observed. However, lower than expected enrolment is likely to have diluted the effects of the programme at a population level.

来源:Emerg Med J,查看原文。版权归原作者所有。

参考来源

  1. Beaney T, Clarke J, Alboksmaty A, et al. Population-level impact of a pulse oximetry remote monitoring programme on mortality and healthcare utilisation in the people with COVID-19 in England: a national analysis using a stepped wedge design. Emerg Med J. 2022. PMID: 35418406. doi:10.1136/emermed-2022-212378

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。